WO2019180272A1 - Réactifs d'affinité anti-leptine destinés à être utilisés dans le traitement de l'obésité et d'autres maladies associées à la résistance à la leptine - Google Patents

Réactifs d'affinité anti-leptine destinés à être utilisés dans le traitement de l'obésité et d'autres maladies associées à la résistance à la leptine Download PDF

Info

Publication number
WO2019180272A1
WO2019180272A1 PCT/EP2019/057435 EP2019057435W WO2019180272A1 WO 2019180272 A1 WO2019180272 A1 WO 2019180272A1 EP 2019057435 W EP2019057435 W EP 2019057435W WO 2019180272 A1 WO2019180272 A1 WO 2019180272A1
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
affinity reagent
antibody
use according
administered
Prior art date
Application number
PCT/EP2019/057435
Other languages
English (en)
Inventor
Marcos COUSELO CAREIRA
Ana Belén CRUJEIRAS MARTÍNEZ
Felipe Casanueva Freijo
Original Assignee
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela
Servizo Galego De Saúde
Universidade De Santiago De Compostela
Consorcio Centro de Investigación Biomédica en Red, M.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Instituto De Investigación Sanitaria De Santiago De Compostela, Servizo Galego De Saúde, Universidade De Santiago De Compostela, Consorcio Centro de Investigación Biomédica en Red, M.P. filed Critical Fundación Instituto De Investigación Sanitaria De Santiago De Compostela
Publication of WO2019180272A1 publication Critical patent/WO2019180272A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

La présente invention concerne des ligands d'affinité anti-leptine (par exemple, des anticorps anti-leptine) qui se lient spécifiquement à la leptine et réduisent ses taux sériques pour une utilisation dans un procédé de traitement d'une maladie associée à la résistance à la leptine, telle que l'obésité et/ou le surpoids, chez un sujet en ayant besoin. L'invention concerne en outre des compositions les comprenant, ainsi que des procédés de traitement comprenant l'administration d'une dose thérapeutiquement efficace de celles-ci.
PCT/EP2019/057435 2018-03-23 2019-03-25 Réactifs d'affinité anti-leptine destinés à être utilisés dans le traitement de l'obésité et d'autres maladies associées à la résistance à la leptine WO2019180272A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382204 2018-03-23
EP18382204.8 2018-03-23

Publications (1)

Publication Number Publication Date
WO2019180272A1 true WO2019180272A1 (fr) 2019-09-26

Family

ID=62002607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/057435 WO2019180272A1 (fr) 2018-03-23 2019-03-25 Réactifs d'affinité anti-leptine destinés à être utilisés dans le traitement de l'obésité et d'autres maladies associées à la résistance à la leptine

Country Status (1)

Country Link
WO (1) WO2019180272A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11732037B2 (en) 2018-06-16 2023-08-22 Board of Regents, The University of Texas Svstem Weight loss regimen

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002809A1 (fr) 1988-09-02 1990-03-22 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
WO1991017271A1 (fr) 1990-05-01 1991-11-14 Affymax Technologies N.V. Procedes de triage de banques d'adn recombine
WO1992001047A1 (fr) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Procede de production de chainon de paires a liaison specifique
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
WO1992015679A1 (fr) 1991-03-01 1992-09-17 Protein Engineering Corporation Phage de visualisation d'un determinant antigenique ameliore
WO1992018619A1 (fr) 1991-04-10 1992-10-29 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
WO1993001288A1 (fr) 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide utile pour trier des anticorps
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
US20030070185A1 (en) 1996-12-03 2003-04-10 Aya Jakobovits Transgenic mammals having human Ig loci including plural Vh and Vk regions and antibodies produced therefrom

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1990002809A1 (fr) 1988-09-02 1990-03-22 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1991017271A1 (fr) 1990-05-01 1991-11-14 Affymax Technologies N.V. Procedes de triage de banques d'adn recombine
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
WO1992001047A1 (fr) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Procede de production de chainon de paires a liaison specifique
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
WO1992015679A1 (fr) 1991-03-01 1992-09-17 Protein Engineering Corporation Phage de visualisation d'un determinant antigenique ameliore
WO1992018619A1 (fr) 1991-04-10 1992-10-29 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
WO1993001288A1 (fr) 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide utile pour trier des anticorps
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US20030070185A1 (en) 1996-12-03 2003-04-10 Aya Jakobovits Transgenic mammals having human Ig loci including plural Vh and Vk regions and antibodies produced therefrom

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
"Current Trends in Monoclonal Antibody Development and manufacturing", 2010, SPRINGER
"Remington's Pharmaceutical Sciences", 1980
A. M. DEPAOLI: "20 YEARS OF LEPTIN: Leptin in common obesity and associated disorders of metabolism", JOURNAL OF ENDOCRINOLOGY, vol. 223, no. 1, 27 June 2014 (2014-06-27), GB, pages T71 - T81, XP055491914, ISSN: 0022-0795, DOI: 10.1530/JOE-14-0258 *
ANTIBODIES: "A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
BANKS WA ET AL., PEPTIDES, vol. 20, no. 11, 1999, pages 1341 - 1345
BANKS WA ET AL., PHYSIOL BEHAV., vol. 105, no. 1, 2011, pages 145 - 9
BANTA, S. ET AL., ANNU. REV. BIOMED. ENG., vol. 15, 2010, pages 93 - 113
CARO JF ET AL., LANCET, vol. 348, no. 9021, 1996, pages 159 - 161
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
COPPARI R; BJORBAEK C., NAT REV DRUG DISCOV., vol. 11, no. 9, 2012, pages 692 - 708
EL-HASCHIMI K ET AL., J CLIN INVEST., vol. 105, no. 12, 2000, pages 1827 - 1832
GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
LEPTIN, HOMO SAPIENS, vol. 1, 1 February 1995 (1995-02-01), Retrieved from the Internet <URL:http://www.uniprot.org/uniprot/P41159>
LEPTIN, RATTUS NORVEGICUS, vol. 1, 1 October 1996 (1996-10-01), Retrieved from the Internet <URL:http://www.uniprot.org/uniprot/P50596>
LOFBLOM, J. ET AL., CURR. OPIN. BIOTECHNOL., vol. 22, 2011, pages 843 - 848
LOFBLOM, J. ET AL., CURR. OPIN. BIOTECHNOL.,, vol. 22, 2011, pages 843 - 848
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
OBER, INTERN. IMMUNOLOGY, vol. 13, 2001, pages 1551 - 1559
OLGA GRUZDEVA ET AL: "Leptin resistance: underlying mechanisms and diagnosis", DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY, vol. Volume 12, 1 January 2019 (2019-01-01), pages 191 - 198, XP055594299, DOI: 10.2147/DMSO.S182406 *
PORTOLANO ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 150, 1993, pages 880 - 887
REAGAN-SHAW ET AL.: "Dose translation from animal to human studies revisited", THE FASEB JOURNAL, vol. 22, 2007, pages 659 - 661, XP007916336
SMITH, SCIENCE, vol. 228, 1985, pages 1315 - 1317
TABRIZI ET AL., DRUG DISCOVERY TODAY, vol. 11, no. 1-2, 2006, pages 81 - 8
WEIDLE ET AL., CANCER GENOMICS & PROTEOMICS, vol. 10, 2013, pages 1 - 18
Z.D. SHI ET AL: "Effects of immunisation against leptin on feed intake, weight gain, fat deposition and laying performance in chickens", BRITISH POULTRY SCIENCE., vol. 47, no. 1, 1 February 2006 (2006-02-01), GB, pages 88 - 94, XP055492779, ISSN: 0007-1668, DOI: 10.1080/00071660500475319 *
ZHANG Y ET AL., NATURE, vol. 372, 1994, pages 425 - 432
ZHOU Y.; RUI L., FRONT MED., vol. 7, no. 2, 2013, pages 207 - 22

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11732037B2 (en) 2018-06-16 2023-08-22 Board of Regents, The University of Texas Svstem Weight loss regimen

Similar Documents

Publication Publication Date Title
KR101889466B1 (ko) FcRn 특이적 인간 항체 및 이를 포함하는 자가면역질환 치료용 조성물
TWI605061B (zh) 會結合及阻斷表現在骨髓細胞上觸發受體－１（ｔｒｅｍ－１）之抗體
IL261809B1 (en) Treatment of inflammatory diseases with inhibitors of C5A activity
JP6633108B2 (ja) 脂肪組織の集積を処置するための組成物および方法
BR112019017308A2 (pt) anticorpos anti-il31 para uso veterinário
CN113164766A (zh) RGMc选择性抑制剂及其用途
AU2019339452A1 (en) Anti-trem-2 agonist antibodies
WO2017035176A1 (fr) Procédé de prévention ou de traitement de l&#39;obésité à l&#39;aide d&#39;un inhibiteur d&#39;emc10
JP2022141801A (ja) 抗ｂｍｐ６抗体またはその抗原結合フラグメント、および組み合わせ物
JP2019162119A (ja) Ｉｌ−１７ｃに対する抗体
US11866513B2 (en) Anti-TMPRSS6 antibodies and uses thereof
WO2019180272A1 (fr) Réactifs d&#39;affinité anti-leptine destinés à être utilisés dans le traitement de l&#39;obésité et d&#39;autres maladies associées à la résistance à la leptine
EP3697821A1 (fr) Procédé
WO2020125744A1 (fr) Protéine bispécifique
EP3717514A1 (fr) Anticorps monoclonaux anti-trkb et leurs procédés d&#39;utilisation
TW202313105A (zh) 與貝伐單抗的抗葉酸受體結合物組合療法
US20230295345A1 (en) Anti-tmprss6 antibodies and uses thereof
RU2784486C1 (ru) Биспецифический белок
US20240043562A1 (en) Musk activation
TWI623324B (zh) 用於治療自體免疫病的與fcrn結合的抗體
KR20240046502A (ko) 섬유성 질환 치료에 있어서 알파-에놀라제 길항제의 이용
JP2023523919A (ja) ヒト化抗ヒトｃｄ８９抗体及びその使用
CN117881784A (zh) 抗生长激素抗体
BR122022016112B1 (pt) Usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a c5

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19714365

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19714365

Country of ref document: EP

Kind code of ref document: A1